Pyxis Oncology (NASDAQ:PYXS) Issues Quarterly Earnings Results, Beats Expectations By $0.06 EPS

Key Points

• Pyxis Oncology reported an earnings per share (EPS) of ($0.30), exceeding expectations by $0.06, while generating $2.82 million in revenue for the quarter.
• The company's stock increased by 8.8% following the earnings announcement, reaching a price of $1.23.
• HC Wainwright maintained a "buy" rating on Pyxis Oncology with a target price set at $5.00, indicating positive growth expectations.

Pyxis Oncology (NASDAQ:PYXS - Get Free Report) released its earnings results on Thursday. The company reported ($0.30) EPS for the quarter, topping the consensus estimate of ($0.36) by $0.06, Zacks reports. The business had revenue of $2.82 million for the quarter.

Pyxis Oncology Stock Up 8.8%

NASDAQ:PYXS traded up $0.10 on Friday, hitting $1.23. The stock had a trading volume of 673,225 shares, compared to its average volume of 359,875. The business's fifty day moving average is $1.16 and its 200 day moving average is $1.16. The company has a market cap of $76.20 million, a PE ratio of -0.77 and a beta of 1.13. Pyxis Oncology has a 52 week low of $0.83 and a 52 week high of $5.39.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright reaffirmed a "buy" rating and set a $5.00 target price on shares of Pyxis Oncology in a research note on Monday, May 19th.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Jane Street Group LLC bought a new position in shares of Pyxis Oncology in the second quarter valued at approximately $370,000. Marshall Wace LLP bought a new position in shares of Pyxis Oncology in the second quarter valued at approximately $163,000. Acadian Asset Management LLC bought a new position in shares of Pyxis Oncology in the first quarter valued at approximately $81,000. Bridgeway Capital Management LLC lifted its holdings in shares of Pyxis Oncology by 76.1% in the second quarter. Bridgeway Capital Management LLC now owns 142,295 shares of the company's stock valued at $157,000 after purchasing an additional 61,500 shares in the last quarter. Finally, Qube Research & Technologies Ltd lifted its holdings in shares of Pyxis Oncology by 128.4% in the second quarter. Qube Research & Technologies Ltd now owns 103,063 shares of the company's stock valued at $113,000 after purchasing an additional 57,935 shares in the last quarter. Institutional investors own 39.09% of the company's stock.

About Pyxis Oncology

Pyxis Oncology, Inc, a clinical stage company, engages in the development of therapeutics to treat cancers. Its lead antibody-drug conjugates (ADC) product candidate is PYX-201, an investigational novel ADC consisting of human immunoglobulin G1 (IgG1), which is in Phase 1 clinical trial to treat patients with relapsed or refractory solid tumors; and lead immuno-oncology (IO) product candidate is PYX-106, an investigational fully human IgG1 Siglec-15-targeting antibody that is in Phase 1 clinical trial to treat patients with advanced solid tumors.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.